Comparative Pharmacodynamics and Pharmacokinetics of Conventional and Long‐Acting Propranolol

@article{Garg1987ComparativePA,
  title={Comparative Pharmacodynamics and Pharmacokinetics of Conventional and Long‐Acting Propranolol},
  author={Dyal C. Garg and Nader S. Jallad and Amal Mishriki and G Chalavarya and M. Kraml and M Fencik and Donald J. Weidler},
  journal={The Journal of Clinical Pharmacology},
  year={1987},
  volume={27}
}
This investigation was conducted to compare the pharmacokinetic and pharmacodynamic effects of single and multiple doses of conventional propranolol and long‐acting propranolol in healthy human volunteers. Two double‐blind, randomized, double‐crossover, Latin square studies were carried out. One study evaluated long‐acting propranolol 160 mg/d, conventional propranolol 40 mg qid, or placebo for seven days in 24 men. The other study compared long‐acting propranolol 80 mg/d, conventional… 
14 Citations
Pharmacokinetics and Pharmacodynamics of Long‐Acting Propranolol 60‐mg Capsules: A Comparative Evaluation
TLDR
This study demonstrates that LA 60 mg displays characteristics of a sustained‐release formulation, is proportional with LA 80 mg, and produces pharmacodynamic effects that are similar to 20‐mg tid dosing.
Pharmacokinetic and Pharmacodynamic Evaluation During Coadministration of Nefazodone and Propranolol in Healthy Men
TLDR
The nature, frequency, and severity of adverse events during coadministration of nefazodone and propranolol were similar to those observed with either treatment alone, and there were no clinically significant effects on vital signs, electrocardiographic results, or laboratory parameters.
Pharmacokinetics and pharmacodynamics of conventional and controlled-release formulations of metipranolol in man
TLDR
Relatively constant plasma concentrations and a clinically significant reduction of exercise-induced tachycardia were maintained throughout a 24 h dosing interval and an individual deacetylmetipranolol plasma concentration-effect relationship was evaluated using the Emax model.
Clinical Pharmacokinetics of Propranolol Hydrochloride: A Review.
TLDR
Physiochemical and pooled pharmacokinetic parameters of propranolol are beneficial in order to establish physiologically based pharmacokinetics modeling among the diseased population.
Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine
TLDR
The very high pharmacokinetic variability of metoprolol and propranolol can result in very high plasma concentrations in a small minority of patients, and those drugs should therefore be titrated up from a low initial dose, depending mainly on the occurrence of adverse events.
Pharmacodynamics of propranolol on left ventricular function: Assessment by Doppler echocardiography
TLDR
The relationship of left ventricular systolic function and heart rate to serum 1‐propranolol concentrations was determined in 10 healthy male volunteers during maximal exercise treadmill testing and data indicate that the concentration‐effect relationship for 1‐ Propranolols and its negative inotropic effect differ from its negative chronotropic effect.
Bioavailability and In‐vitro/in‐vivo Correlation for Propranolol Hydrochloride Extended‐release Bead Products Prepared Using Aqueous Polymeric Dispersions
The influence of formulation and extrinsic factors has been investigated for the in‐vitro release of propranolol hydrochloride from controlled‐release beads prepared using aqueous polymeric
Determination of propranolol in dog plasma by HPLC method
A rapid, sensitive and accurate high performance liquid chromatographic (HPLC) method for determination of propranolol in dog plasma is described. Propranolol was extracted from dog plasma using a
Formulation and Evaluation of Kollidon® SR for PH-Independent Extended Release Matrix Systems for Propranolol Hydrochloride
TLDR
Kollidon® SR is a potentially useful excipient for the production of pH-independent extended release matrix tablets and was the main release controlling agent in the presence of an external binder or enteric polymer in the matrix.
Development of pH-independent matrix type sustained release drug delivery system of propranolol hydrochloride
TLDR
Kollidon® SR is a potentially useful excipient for the production of pH-independent extended release matrix tablets and was the main release controlling agent in the presence of an external binder or enteric polymer in the matrix.
...
...

References

SHOWING 1-10 OF 11 REFERENCES
Pharmacokinetic and pharmacodynamic studies with long-acting propranolol.
TLDR
The whole blood concentrations of propranolol have been compared, over a 48 h period, in twelve healthy male volunteers dosed with a 160 mg long-acting capsule formulation and three standard tablet regimens; 160 mg once a day, 80 mg twice a day and 40 mg four times a day.
Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol.
TLDR
The observations show that the new long acting formulation of propranolol produces a significant reduction of an exercise tachycardia throughout a 24 h period without a very high initial effect during single and multiple dosing.
Dynamics of propranolol dosing schedules
TLDR
The data indicate that propranolol twice rather than three times a day should be favored when β1‐blockade is needed in therapy and that both twice‐ and three‐times‐a‐day dosing schedules provide well‐sustained 24‐hr β‐ blockade and are probably interchangeable for therapeutic purposes.
Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol.
TLDR
The plasma concentration of metoprolol declined mono-exponentially with time at a rate corresponding to an elimination half-life of about three hours, indicating a bioavailability of 40–50% for the two highest oral doses and a ratio between equipotent oral and intravenous doses about 2.5.
Plasma propranolol levels in adults With observations in four children
TLDR
Plasma levels of the f3‐adrenergic‐blocking drug, propranolol, have been measured fluorometrically in man after oral and intravenous administration, indicating considerable variability among individuals in the amount of drug reaching the systemiC circulation after oral administration.
Clinical Pharmacokinetics of Propranolol
TLDR
Hepatic, renal, thyroid and some gastrointestinal diseases as well as hypertension, malnutrition and hypothermia may be associated with alterations in propranolol disposition, all of which are consistent with the pathophysiology of these diseases.
Propranolol dosage, plasma concentration, and beta blockade
TLDR
The relation of propranolol dose and plasma levels to beta blockade in normal subjects appears to reflect observations in large clinical trials.
Drug Concentrations in the Plasma as an Index of Pharmacologic Effect
TLDR
Although this approach has been shown to be clinically useful, it obviously does not differentiate those patients who have an intrinsic clinical response to a drug which is different from the normal population of patients, i.e., drug-semisitive or drug-resistant individuals.
The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension.
1 The effects on heart rate and blood pressure after single and multiple dosing (1 month) of a long acting formulation of propranolol 160 mg daily, and conventional propranolol, 80 mg twice daily, or
Dubuc J , ot at : Propranolol concentrations in healthy men given 80 mg daily in divided doses : Effect of food and circadian variation
  • Curr 1 ’ her Res
  • 1982
...
...